Current perspectives on HIV-1 antiretroviral drug resistance

Viruses

Volumn 6, Issue 10, 2014, Pages 4095-4139

  Iyidogan, Pinar ^a   Anderson, Karen S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral therapy; Drug resistance; Evolution; HIV 1; Lethal mutagenesis; Resistance monitoring

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ANTIVIRAL RESISTANCE; EXCISION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MONITORING; MUTAGENESIS; MUTATION RATE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; VIRUS ENTRY; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTAGENESIS;

EID: 84908242050     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v6104095     Document Type: Review

References (309)

1. Barre-Sinoussi, F. Hiv as the cause of aids. Lancet 1996, 348, 31-35.
2. WHO. Unaids Report on the Global Aids Epidemic 2013. Available onine: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf (accessed on 16 June 2014).
3. De Clercq, E. Human viral diseases: What is next for antiviral drug discovery? Curr. Opin. Virol. 2012, 2, 572-579.
4. De Clercq, E. Anti-hiv drugs: 25 compounds approved within 25 years after the discovery of hiv. Int. J. Antimicrob. Agents 2009, 33, 307-320.
5. Chen, R.; Quinones-Mateu, M.E.; Mansky, L.M. Hiv-1 mutagenesis during antiretroviral therapy: Implications for successful drug treatment. Front. Biosci. 2005, 10, 743-750.
6. Burke, D.S. Recombination in hiv: An important viral evolutionary strategy. Emerg. Infect. Dis. 1997, 3, 253-259.
7. Mansky, L.M.; Temin, H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 1995, 69, 5087-5094.
8. Sanjuan, R.; Nebot, M.R.; Chirico, N.; Mansky, L.M.; Belshaw, R. Viral mutation rates. J. Virol. 2010, 84, 9733-9748.
9. Ho, D.D.; Neumann, A.U.; Perelson, A.S.; Chen, W.; Leonard, J.M.; Markowitz, M. Rapid turnover of plasma virions and cd4 lymphocytes in hiv-1 infection. Nature 1995, 373, 123-126.
10. Wei, X.; Ghosh, S.K.; Taylor, M.E.; Johnson, V.A.; Emini, E.A.; Deutsch, P.; Lifson, J.D.; Bonhoeffer, S.; Nowak, M.A.; Hahn, B.H., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373, 117-122.
11. Perelson, A.S.; Neumann, A.U.; Markowitz, M.; Leonard, J.M.; Ho, D.D. Hiv-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271, 1582-1586.
12. Chun, T.W.; Carruth, L.; Finzi, D.; Shen, X.; DiGiuseppe, J.A.; Taylor, H.; Hermankova, M.; Chadwick, K.; Margolick, J.; Quinn, T.C., et al. Quantification of latent tissue reservoirs and total body viral load in hiv-1 infection. Nature 1997, 387, 183-188.
13. Jung, A.; Maier, R.; Vartanian, J.P.; Bocharov, G.; Jung, V.; Fischer, U.; Meese, E.; Wain-Hobson, S.; Meyerhans, A. Recombination: Multiply infected spleen cells in hiv patients. Nature 2002, 418, 144.
14. Keele, B.F.; Giorgi, E.E.; Salazar-Gonzalez, J.F.; Decker, J.M.; Pham, K.T.; Salazar, M.G.; Sun, C.; Grayson, T.; Wang, S.; Li, H., et al. Identification and characterization of transmitted and early founder virus envelopes in primary hiv-1 infection. Proc. Natl. Acad. Sci. USA 2008, 105, 7552-7557.
15. Temin, H.M. Is hiv unique or merely different? J. Acquir. Immune Defic. Syndr. 1989, 2, 1-9.
16. Coffin, J.M. Hiv population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995, 267, 483-489.
17. Domingo, E.; Holland, J.J. Rna virus mutations and fitness for survival. Annu. Rev. Microbiol. 1997, 51, 151-178.
18. Eigen, M. On the nature of virus quasispecies. Trends Microbiol. 1996, 4, 216-218.
19. Holland, J.J.; de la Torre, J.C.; Steinhauer, D.A. Rna virus populations as quasispecies. Curr. Top. Microbiol. Immunol. 1992, 176, 1-20.
20. Eigen, M.; Schuster, P. The Hypercycle: A Principle of Natural Self-Organization; Springer: Berlin, Germany, 1979.
21. Domingo, E.; Wu, H.; Lien, E.J.; Lien, L.L.; Schultz, R.M.; Ram, V.J.; Spence, P.; Gupta, S.P.; Bhat, S.P.; Villarreal, E.C. Quasispecies and the development of new antiviral strategies. In Progress Drug Research; Jucker, E., Ed.; Birkhäuser Verlag: Basel, Switzerland, 2003; Volume 60, pp. 133-158.
22. Biebricher, C.K.; Eigen, M. What is a quasispecies? Curr. Top. Microbiol. Immunol. 2006, 299, 1-31.
23. Rouzine, I.M.; Brunet, E.; Wilke, C.O. The traveling-wave approach to asexual evolution: Muller’s ratchet and speed of adaptation. Theor. Popul. Biol. 2008, 73, 24-46.
24. Bull, J.J.; Sanjuan, R.; Wilke, C.O. Theory of lethal mutagenesis for viruses. J. Virol. 2007, 81, 2930-2939.
25. Mansky, L.M. Retrovirus mutation rates and their role in genetic variation. J. Gen. Virol. 1998, 79 (Pt 6), 1337-1345.
26. Nowak, M.A.; Anderson, R.M.; McLean, A.R.; Wolfs, T.F.; Goudsmit, J.; May, R.M. Antigenic diversity thresholds and the development of aids. Science 1991, 254, 963-969.
27. Mansky, L.M. Hiv mutagenesis and the evolution of antiretroviral drug resistance. Drug Resist. Updates 2002, 5, 219-223.
28. Preston, B.D.; Dougherty, J.P. Mechanisms of retroviral mutation. Trends Microbiol. 1996, 4, 16-21.
29. Menendez-Arias, L. Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. Prog. Nucleic Acid Res. Mol. Biol. 2002, 71, 91-147.
30. Jonckheere, H.; Anne, J.; de Clercq, E. The hiv-1 reverse transcription (rt) process as target for rt inhibitors. Med. Res. Rev. 2000, 20, 129-154.
31. Roberts, J.D.; Bebenek, K.; Kunkel, T.A. The accuracy of reverse transcriptase from hiv-1. Science 1988, 242, 1171-1173.
32. Preston, B.D.; Poiesz, B.J.; Loeb, L.A. Fidelity of hiv-1 reverse transcriptase. Science 1988, 242, 1168-1171.
33. Roberts, J.D.; Preston, B.D.; Johnston, L.A.; Soni, A.; Loeb, L.A.; Kunkel, T.A. Fidelity of two retroviral reverse transcriptases during DNA-dependent DNA synthesis in vitro. Mol. Cell. Biol. 1989, 9, 469-476.
34. Steinhauer, D.A.; Domingo, E.; Holland, J.J. Lack of evidence for proofreading mechanisms associated with an rna virus polymerase. Gene 1992, 122, 281-288.
35. Zhang, J. Host rna polymerase ii makes minimal contributions to retroviral frame-shift mutations. J. Gen. Virol. 2004, 85, 2389-2395.
36. O’Neil, P.K.; Sun, G.; Yu, H.; Ron, Y.; Dougherty, J.P.; Preston, B.D. Mutational analysis of hiv-1 long terminal repeats to explore the relative contribution of reverse transcriptase and rna polymerase ii to viral mutagenesis. J. Biol. Chem. 2002, 277, 38053-38061.
37. Harris, R.S.; Liddament, M.T. Retroviral restriction by apobec proteins. Nat. Rev. Immunol. 2004, 4, 868-877.
38. Malim, M.H.; Emerman, M. Hiv-1 accessory proteins—Ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3, 388-398.
39. Chiu, Y.L.; Greene, W.C. The apobec3 cytidine deaminases: An innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 2008, 26, 317-353.
40. Sheehy, A.M.; Gaddis, N.C.; Choi, J.D.; Malim, M.H. Isolation of a human gene that inhibits hiv-1 infection and is suppressed by the viral vif protein. Nature 2002, 418, 646-650.
41. Mangeat, B.; Turelli, P.; Caron, G.; Friedli, M.; Perrin, L.; Trono, D. Broad antiretroviral defence by human apobec3g through lethal editing of nascent reverse transcripts. Nature 2003, 424, 99-103.
42. Mariani, R.; Chen, D.; Schrofelbauer, B.; Navarro, F.; Konig, R.; Bollman, B.; Munk, C.; Nymark-McMahon, H.; Landau, N.R. Species-specific exclusion of apobec3g from hiv-1 virions by vif. Cell 2003, 114, 21-31.
43. KewalRamani, V.N.; Coffin, J.M. Virology. Weapons of mutational destruction. Science 2003, 301, 923-925.
44. Bhagwat, A.S. DNA-cytosine deaminases: From antibody maturation to antiviral defense. DNA Repair 2004, 3, 85-89.
45. Aires da Silva, F.; Santa-Marta, M.; Freitas-Vieira, A.; Mascarenhas, P.; Barahona, I.; Moniz-Pereira, J.; Gabuzda, D.; Goncalves, J. Camelized rabbit-derived vh single-domain intrabodies against vif strongly neutralize hiv-1 infectivity. J. Mol. Biol. 2004, 340, 525-542.
46. Harris, R.S.; Bishop, K.N.; Sheehy, A.M.; Craig, H.M.; Petersen-Mahrt, S.K.; Watt, I.N.; Neuberger, M.S.; Malim, M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113, 803-809.
47. Lecossier, D.; Bouchonnet, F.; Clavel, F.; Hance, A.J. Hypermutation of hiv-1 DNA in the absence of the vif protein. Science 2003, 300, 1112.
48. Zhang, H.; Yang, B.; Pomerantz, R.J.; Zhang, C.; Arunachalam, S.C.; Gao, L. The cytidine deaminase cem15 induces hypermutation in newly synthesized hiv-1 DNA. Nature 2003, 424, 94-98.
49. Goff, S.P. Death by deamination: A novel host restriction system for hiv-1. Cell 2003, 114, 281-283.
50. Lavens, D.; Peelman, F.; van der Heyden, J.; Uyttendaele, I.; Catteeuw, D.; Verhee, A.; van Schoubroeck, B.; Kurth, J.; Hallenberger, S.; Clayton, R., et al. Definition of the interacting interfaces of apobec3g and hiv-1 vif using mappit mutagenesis analysis. Nucleic Acids Res. 2010, 38, 1902-1912.
51. Goncalves, J.; Santa-Marta, M. Hiv-1 vif and apobec3g: Multiple roads to one goal. Retrovirology 2004, 1, 28.
52. Cadima-Couto, I.; Goncalves, J. Towards inhibition of vif-apobec3g interaction: Which protein to target? Adv. Virol. 2010, 2010, 649315.
53. Munk, C.; Jensen, B.E.; Zielonka, J.; Haussinger, D.; Kamp, C. Running loose or getting lost: How hiv-1 counters and capitalizes on apobec3-induced mutagenesis through its vif protein. Viruses 2012, 4, 3132-3161.
54. Orr, H.A. The rate of adaptation in asexuals. Genetics 2000, 155, 961-968.
55. Zhuang, J.; Jetzt, A.E.; Sun, G.; Yu, H.; Klarmann, G.; Ron, Y.; Preston, B.D.; Dougherty, J.P. Human immunodeficiency virus type 1 recombination: Rate, fidelity, and putative hot spots. J. Virol. 2002, 76, 11273-11282.
56. Mulder, L.C.; Harari, A.; Simon, V. Cytidine deamination induced hiv-1 drug resistance. Proc. Natl. Acad. Sci. USA 2008, 105, 5501-5506.
57. Hu, W.S.; Temin, H.M. Retroviral recombination and reverse transcription. Science 1990, 250, 1227-1233.
58. Zhang, J.; Tang, L.Y.; Li, T.; Ma, Y.; Sapp, C.M. Most retroviral recombinations occur during minus-strand DNA synthesis. J. Virol. 2000, 74, 2313-2322.
59. Yu, H.; Jetzt, A.E.; Ron, Y.; Preston, B.D.; Dougherty, J.P. The nature of human immunodeficiency virus type 1 strand transfers. J. Biol. Chem. 1998, 273, 28384-28391.
60. Jetzt, A.E.; Yu, H.; Klarmann, G.J.; Ron, Y.; Preston, B.D.; Dougherty, J.P. High rate of recombination throughout the human immunodeficiency virus type 1 genome. J. Virol. 2000, 74, 1234-1240.
61. Levy, D.N.; Aldrovandi, G.M.; Kutsch, O.; Shaw, G.M. Dynamics of hiv-1 recombination in its natural target cells. Proc. Natl. Acad. Sci. USA 2004, 101, 4204-4209.
62. Althaus, C.L.; Bonhoeffer, S. Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J. Virol. 2005, 79, 13572-13578.
63. Nora, T.; Charpentier, C.; Tenaillon, O.; Hoede, C.; Clavel, F.; Hance, A.J. Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment. J. Virol. 2007, 81, 7620-7628.
64. Bretscher, M.T.; Althaus, C.L.; Muller, V.; Bonhoeffer, S. Recombination in hiv and the evolution of drug resistance: For better or for worse? BioEssays 2004, 26, 180-188.
65. Perales, C.; Iranzo, J.; Manrubia, S.C.; Domingo, E. The impact of quasispecies dynamics on the use of therapeutics. Trends Microbiol. 2012, 20, 595-603.
66. Mullins, J.I.; Jensen, M.A. Evolutionary dynamics of hiv-1 and the control of aids. Curr. Top. Microbiol. Immunol. 2006, 299, 171-192.
67. Gao, F.; Chen, Y.; Levy, D.N.; Conway, J.A.; Kepler, T.B.; Hui, H. Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious. J. Virol. 2004, 78, 2426-2433.
68. Loeb, L.A.; Essigmann, J.M.; Kazazi, F.; Zhang, J.; Rose, K.D.; Mullins, J.I. Lethal mutagenesis of hiv with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. USA 1999, 96, 1492-1497.
69. Grande-Perez, A.; Lazaro, E.; Lowenstein, P.; Domingo, E.; Manrubia, S.C. Suppression of viral infectivity through lethal defection. Proc. Natl. Acad. Sci. USA 2005, 102, 4448-4452.
70. Huber-Ruano, I.; Pastor-Anglada, M. Transport of nucleoside analogs across the plasma membrane: A clue to understanding drug-induced cytotoxicity. Curr. Drug Metab. 2009, 10, 347-358.
71. Eriksson, S.; Wang, L. The role of the cellular deoxynucleoside kinases in activation of nucleoside analogs used in chemotherapy. In Recent Advances in Nucleosides: Chemistry and Chemotherapy; Chu, C.K., Ed.; Elsevier: New York, NY, USA, 2002; pp. 465-468.
72. Loeb, L.A.; Mullins, J.I. Lethal mutagenesis of hiv by mutagenic ribonucleoside analogs. AIDS Res. Hum. Retrovir. 2000, 16, 1-3.
73. Kamath-Loeb, A.S.; Hizi, A.; Tabone, J.; Solomon, M.S.; Loeb, L.A. Inefficient repair of rna x DNA hybrids. Eur. J. Biochem./FEBS 1997, 250, 492-501.
74. Suen, W.; Spiro, T.G.; Sowers, L.C.; Fresco, J.R. Identification by uv resonance raman spectroscopy of an imino tautomer of 5-hydroxy-2'-deoxycytidine, a powerful base analog transition mutagen with a much higher unfavored tautomer frequency than that of the natural residue 2'-deoxycytidine. Proc. Natl. Acad. Sci. USA 1999, 96, 4500-4505.
75. Smith, R.A.; Loeb, L.A.; Preston, B.D. Lethal mutagenesis of hiv. Virus Res. 2005, 107, 215-228.
76. Anderson, J.P.; Daifuku, R.; Loeb, L.A. Viral error catastrophe by mutagenic nucleosides. Annu. Rev. Microbiol. 2004, 58, 183-205.
77. Issa, J.P.; Kantarjian, H. Azacitidine. Nat. Rev. 2005, Suppl, S6-S7.
78. Bouchard, J.; Walker, M.C.; Leclerc, J.M.; Lapointe, N.; Beaulieu, R.; Thibodeau, L. 5-azacytidine and 5-azadeoxycytidine inhibit human immunodeficiency virus type 1 replication in vitro. Antimicrob. Agents Chemother. 1990, 34, 206-209.
79. Dapp, M.J.; Clouser, C.L.; Patterson, S.; Mansky, L.M. 5-azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J. Virol. 2009, 83, 11950-11958.
80. Clouser, C.L.; Patterson, S.E.; Mansky, L.M. Exploiting drug repositioning for discovery of a novel hiv combination therapy. J. Virol. 2010, 84, 9301-9309.
81. Rogstad, D.K.; Herring, J.L.; Theruvathu, J.A.; Burdzy, A.; Perry, C.C.; Neidigh, J.W.; Sowers, L.C. Chemical decomposition of 5-aza-2'-deoxycytidine (decitabine): Kinetic analyses and identification of products by nmr, hplc, and mass spectrometry. Chem. Res. Toxicol. 2009, 22, 1194-1204.
82. Jackson-Grusby, L.; Laird, P.W.; Magge, S.N.; Moeller, B.J.; Jaenisch, R. Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc. Natl. Acad. Sci. USA 1997, 94, 4681-4685.
83. Pathak, V.K.; Temin, H.M. 5-azacytidine and rna secondary structure increase the retrovirus mutation rate. J. Virol. 1992, 66, 3093-3100.
84. Harris, K.S.; Brabant, W.; Styrchak, S.; Gall, A.; Daifuku, R. Kp-1212/1461, a nucleoside designed for the treatment of hiv by viral mutagenesis. Antivir. Res. 2005, 67, 1-9.
85. Murakami, E.; Basavapathruni, A.; Bradley, W.D.; Anderson, K.S. Mechanism of action of a novel viral mutagenic covert nucleotide: Molecular interactions with hiv-1 reverse transcriptase and host cell DNA polymerases. Antivir. Res. 2005, 67, 10-17.
86. Johnson, A.A.; Ray, A.S.; Hanes, J.; Suo, Z.; Colacino, J.M.; Anderson, K.S.; Johnson, K.A. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 2001, 276, 40847-40857.
87. Clay, P.G.; McRae, M.; Laurent, J.P. Safety, tolerability, and pharmacokinetics of kp-1461 in phase i clinical studies: A single oral dose study in non-hiv-infected adults, and a 14-day dose-escalating study in highly antiretroviral-experienced hiv-infected adults. J. Int. Assoc. Physicians AIDS Care 2011, 10, 232-238.
88. Mullins, J.I.; Heath, L.; Hughes, J.P.; Kicha, J.; Styrchak, S.; Wong, K.G.; Rao, U.; Hansen, A.; Harris, K.S.; Laurent, J.P., et al. Mutation of hiv-1 genomes in a clinical population treated with the mutagenic nucleoside kp1461. PLoS One 2011, 6, e15135.
89. Hicks, C.; Clay, P.; Redfield, R.; Lalezari, J.; Liporace, R.; Schneider, S.; Sension, M.; McRae, M.; Laurent, J.P. Safety, tolerability, and efficacy of kp-1461 as monotherapy for 124 days in antiretroviral-experienced, hiv type 1-infected subjects. AIDS Res. Hum. Retrovir. 2013, 29, 250-255.
90. Mehellou, Y.; de Clercq, E. Twenty-six years of anti-hiv drug discovery: Where do we stand and where do we go? J. Med. Chem. 2010, 53, 521-538.
91. Sarafianos, S.G.; Marchand, B.; Das, K.; Himmel, D.M.; Parniak, M.A.; Hughes, S.H.; Arnold, E. Structure and function of hiv-1 reverse transcriptase: Molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 2009, 385, 693-713.
92. Arion, D.; Kaushik, N.; McCormick, S.; Borkow, G.; Parniak, M.A. Phenotypic mechanism of hiv-1 resistance to 3'-azido-3'-deoxythymidine (azt): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998, 37, 15908-15917.
93. Meyer, P.R.; Matsuura, S.E.; So, A.G.; Scott, W.A. Unblocking of chain-terminated primer by hiv-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. USA 1998, 95, 13471-13476.
94. Huang, H.; Chopra, R.; Verdine, G.L.; Harrison, S.C. Structure of a covalently trapped catalytic complex of hiv-1 reverse transcriptase: Implicaiton fro drug resistance. Science 1998, 282, 1669-1675.
95. Huang, H.; Chopra, R.; Verdine, G.L.; Harrison, S.C. Structure of a covalently trapped catalytic complex of hiv-1 reverse transcriptase: Implications for drug resistance. Science 1998, 282, 1669-1675.
96. Selmi, B.; Boretto, J.; Sarfati, S.R.; Guerreiro, C.; Canard, B. Mechanism-based suppression of dideoxynucleotide resistance by k65r human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue. J. Biol Chem. 2001, 276, 48466-48472.
97. Deval, J.; Alvarez, K.; Selmi, B.; Bermond, M.; Boretto, J.; Guerreiro, C.; Mulard, L.; Canard, B. Mechanistic insights into the suppression of drug resistance by human immunodeficiency virus type 1 reverse transcriptase using alpha-boranophosphate nucleoside analogs. J. Biol. Chem. 2005, 280, 3838-3846.
98. Sluis-Cremer, N.; Sheen, C.W.; Zelina, S.; Torres, P.S.; Parikh, U.M.; Mellors, J.W. Molecular mechanism by which the k70e mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 2007, 51, 48-53.
99. Deval, J.; White, K.L.; Miller, M.D.; Parkin, N.T.; Courcambeck, J.; Halfon, P.; Selmi, B.; Boretto, J.; Canard, B. Mechanistic basis for reduced viral and enzymatic fitness of hiv-1 reverse transcriptase containing both k65r and m184v mutations. J. Biol. Chem. 2004, 279, 509-516.
100. Feng, J.Y.; Myrick, F.T.; Margot, N.A.; Mulamba, G.B.; Rimsky, L.; Borroto-Esoda, K.; Selmi, B.; Canard, B. Virologic and enzymatic studies revealing the mechanism of k65r-and q151m-associated hiv-1 drug resistance towards emtricitabine and lamivudine. Nucleosides Nucleotides Nucleic Acids 2006, 25, 89-107.
101. Sarafianos, S.G.; Das, K.; Clark, A.D., Jr.; Ding, J.; Boyer, P.L.; Hughes, S.H.; Arnold, E. Lamivudine (3tc) resistance in hiv-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. USA 1999, 96, 10027-10032.
102. Ray, A.S.; Murakami, E.; Peterson, C.N.; Shi, J.; Schinazi, R.F.; Anderson, K.S. Interactions of enantiomers of 2',3'-didehydro-2',3'-dideoxy-fluorocytidine with wild type and m184v mutant hiv-1 reverse transcriptase. Antivir. Res. 2002, 56, 189-205.
103. Gao, H.Q.; Boyer, P.L.; Sarafianos, S.G.; Arnold, E.; Hughes, S.H. The role of steric hindrance in 3tc resistance of human immunodeficiency virus type-1 reverse transcriptase. J. Mol. Biol. 2000, 300, 403-418.
104. Wei, X.; Liang, C.; Gotte, M.; Wainberg, M.A. Negative effect of the m184v mutation in hiv-1 reverse transcriptase on initiation of viral DNA synthesis. Virology 2003, 311, 202-212.
105. Van Cor-Hosmer, S.K.; Daddacha, W.; Kim, B. Mechanistic interplay among the m184i hiv-1 reverse transcriptase mutant, the central polypurine tract, cellular dntp concentrations and drug sensitivity. Virology 2010, 406, 253-260.
106. Marcelin, A.G.; Charpentier, C.; Wirden, M.; Landman, R.; Valantin, M.A.; Simon, A.; Katlama, C.; Yeni, P.; Descamps, D.; Aubron-Olivier, C., et al. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. J. Antimicrob. Chemother. 2012, 67, 1475-1478.
107. Ray, A.S.; Basavapathruni, A.; Anderson, K.S. Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J. Biol. Chem. 2002, 277, 40479-40490.
108. Frangeul, A.; Bussetta, C.; Deval, J.; Barral, K.; Alvarez, K.; Canard, B. Gln151 of hiv-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues. Antivir. Therapy 2008, 13, 115-124.
109. Mbisa, J.L.; Gupta, R.K.; Kabamba, D.; Mulenga, V.; Kalumbi, M.; Chintu, C.; Parry, C.M.; Gibb, D.M.; Walker, S.A.; Cane, P.A., et al. The evolution of hiv-1 reverse transcriptase in route to acquisition of q151m multi-drug resistance is complex and involves mutations in multiple domains. Retrovirology 2011, 8, 31.
110. Hachiya, A.; Kodama, E.N.; Schuckmann, M.M.; Kirby, K.A.; Michailidis, E.; Sakagami, Y.; Oka, S.; Singh, K.; Sarafianos, S.G. K70q adds high-level tenofovir resistance to “q151m complex” hiv reverse transcriptase through the enhanced discrimination mechanism. PLoS One 2011, 6, e16242.
111. Kisic, M.; Mendieta, J.; Puertas, M.C.; Parera, M.; Martinez, M.A.; Martinez-Picado, J.; Menendez-Arias, L. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the hiv-1 reverse transcriptase coding region. J. Mol. Biol. 2008, 382, 327-341.
112. Ding, J.; Das, K.; Hsiou, Y.; Sarafianos, S.G.; Clark, A.D., Jr.; Jacobo-Molina, A.; Tantillo, C.; Hughes, S.H.; Arnold, E. Structure and functional implications of the polymerase active site region in a complex of hiv-1 rt with a double-stranded DNA template-primer and an antibody fab fragment at 2.8 a resolution. J. Mol. Biol. 1998, 284, 1095-1111.
113. Lanier, E.R.; Givens, N.; Stone, C.; Griffin, P.; Gibb, D.; Walker, S.; Tisdale, M.; Irlbeck, D.; Underwood, M.; St Clair, M., et al. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med. 2004, 5, 394-399.
114. Waters, L.; Nelson, M.; Mandalia, S.; Bower, M.; Powles, T.; Gazzard, B.; Stebbing, J. The risks and incidence of k65r and l74v mutations and subsequent virologic responses. Clin. Infect. Dis. 2008, 46, 96-100.
115. Miller, M.D.; Margot, N.; Lu, B.; Zhong, L.; Chen, S.S.; Cheng, A.; Wulfsohn, M. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis. 2004, 189, 837-846.
116. Menendez-Arias, L. Molecular basis of human immunodeficiency virus drug resistance: An update. Antivir. Res. 2010, 85, 210-231.
117. Meyer, P.R.; Matsuura, S.E.; Tolun, A.A.; Pfeifer, I.; So, A.G.; Mellors, J.W.; Scott, W.A. Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 2002, 46, 1540-1545.
118. Ray, A.S.; Murakami, E.; Basavapathruni, A.; Vaccaro, J.A.; Ulrich, D.; Chu, C.K.; Schinazi, R.F.; Anderson, K.S. Probing the molecular mechanisms of azt drug resistance mediated by hiv-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 2003, 42, 8831-8841.
119. Menendez-Arias, L. Mechanisms of resistance to nucleoside analogue inhibitors of hiv-1 reverse transcriptase. Virus Res. 2008, 134, 124-146.
120. Larder, B.A.; Coates, K.E.; Kemp, S.D. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J. Virol. 1991, 65, 5232-5236.
121. Hanna, G.J.; Johnson, V.A.; Kuritzkes, D.R.; Richman, D.D.; Brown, A.J.; Savara, A.V.; Hazelwood, J.D.; D’Aquila, R.T. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J. Infect. Dis. 2000, 181, 904-911.
122. Marcelin, A.G.; Delaugerre, C.; Wirden, M.; Viegas, P.; Simon, A.; Katlama, C.; Calvez, V. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J. Med. Virol. 2004, 72, 162-165.
123. Boyer, P.L.; Sarafianos, S.G.; Arnold, E.; Hughes, S.H. Selective excision of aztmp by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 2001, 75, 4832-4842.
124. Meyer, P.R.; Matsuura, S.E.; Schinazi, R.F.; So, A.G.; Scott, W.A. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob. Agents Chemother. 2000, 44, 3465-3472.
125. Meyer, P.R.; Matsuura, S.E.; Mian, A.M.; So, A.G.; Scott, W.A. A mechanism of azt resistance: An increase in nucleotide-dependent primer unblocking by mutant hiv-1 reverse transcriptase. Mol. Cell 1999, 4, 35-43.
126. Tong, W.; Lu, C.D.; Sharma, S.K.; Matsuura, S.; So, A.G.; Scott, W.A. Nucleotide-induced stable complex formation by hiv-1 reverse transcriptase. Biochemistry 1997, 36, 5749-5757.
127. Marchand, B.; Gotte, M. Site-specific footprinting reveals differences in the translocation status of hiv-1 reverse transcriptase. Implications for polymerase translocation and drug resistance. J. Biol. Chem. 2003, 278, 35362-35372.
128. Marchand, B.; White, K.L.; Ly, J.K.; Margot, N.A.; Wang, R.; McDermott, M.; Miller, M.D.; Gotte, M. Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir. Antimicrob. Agents Chemother. 2007, 51, 2911-2919.
129. Iyidogan, P.; Anderson, K.S. Understanding the molecular mechanism of sequence dependent tenofovir removal by hiv-1 reverse transcriptase: Differences in primer binding site versus polypurine tract. Antivir. Res. 2012, 95, 93-103.
130. Tu, X.; Das, K.; Han, Q.; Bauman, J.D.; Clark, A.D., Jr.; Hou, X.; Frenkel, Y.V.; Gaffney, B.L.; Jones, R.A.; Boyer, P.L., et al. Structural basis of hiv-1 resistance to azt by excision. Nat. Struct. Mol. Biol. 2010, 17, 1202-1209.
131. Dharmasena, S.; Pongracz, Z.; Arnold, E.; Sarafianos, S.G.; Parniak, M.A. 3'-azido-3'-deoxythymidine-(5')-tetraphospho-(5')-adenosine, the product of atp-mediated excision of chain-terminating aztmp, is a potent chain-terminating substrate for hiv-1 reverse transcriptase. Biochemistry 2007, 46, 828-836.
132. Meyer, P.R.; Smith, A.J.; Matsuura, S.E.; Scott, W.A. Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants. Antimicrob. Agents Chemother. 2006, 50, 3607-3614.
133. Eggink, D.; Huigen, M.C.; Boucher, C.A.; Gotte, M.; Nijhuis, M. Insertions in the beta3-beta4 loop of reverse transcriptase of human immunodeficiency virus type 1 and their mechanism of action, influence on drug susceptibility and viral replication capacity. Antivir. Res. 2007, 75, 93-103.
134. Cases-Gonzalez, C.E.; Franco, S.; Martinez, M.A.; Menendez-Arias, L. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant hiv-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine. J. Mol. Biol. 2007, 365, 298-309.
135. Meyer, P.R.; Lennerstrand, J.; Matsuura, S.E.; Larder, B.A.; Scott, W.A. Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J. Virol. 2003, 77, 3871-3877.
136. Boyer, P.L.; Sarafianos, S.G.; Arnold, E.; Hughes, S.H. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves atp-mediated excision. J. Virol. 2002, 76, 9143-9151.
137. Kawamoto, A.; Kodama, E.; Sarafianos, S.G.; Sakagami, Y.; Kohgo, S.; Kitano, K.; Ashida, N.; Iwai, Y.; Hayakawa, H.; Nakata, H., et al. 2'-deoxy-4'-c-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int. J. Biochem. Cell biol. 2008, 40, 2410-2420.
138. Kodama, E.I.; Kohgo, S.; Kitano, K.; Machida, H.; Gatanaga, H.; Shigeta, S.; Matsuoka, M.; Ohrui, H.; Mitsuya, H. 4'-ethynyl nucleoside analogs: Potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob. Agents Chemother. 2001, 45, 1539-1546.
139. Michailidis, E.; Marchand, B.; Kodama, E.N.; Singh, K.; Matsuoka, M.; Kirby, K.A.; Ryan, E.M.; Sawani, A.M.; Nagy, E.; Ashida, N., et al. Mechanism of inhibition of hiv-1 reverse transcriptase by 4'-ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J. Biol. Chem. 2009, 284, 35681-35691.
140. Nakata, H.; Amano, M.; Koh, Y.; Kodama, E.; Yang, G.; Bailey, C.M.; Kohgo, S.; Hayakawa, H.; Matsuoka, M.; Anderson, K.S., et al. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Antimicrob. Agents Chemother. 2007, 51, 2701-2708.
141. Ohrui, H.; Kohgo, S.; Hayakawa, H.; Kodama, E.; Matsuoka, M.; Nakata, T.; Mitsuya, H. 2'-deoxy-4'-c-ethynyl-2-fluoroadenosine: A nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of hiv-1 strains, favorable toxic profiles, and stability in plasma. Nucleosides Nucleotides Nucleic Acids 2007, 26, 1543-1546.
142. Sohl, C.D.; Singh, K.; Kasiviswanathan, R.; Copeland, W.C.; Mitsuya, H.; Sarafianos, S.G.; Anderson, K.S. Mechanism of interaction of human mitochondrial DNA polymerase gamma with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity. Antimicrob. Agents Chemother. 2012, 56, 1630-1634.
143. Muftuoglu, Y.; Sohl, C.D.; Mislak, A.C.; Mitsuya, H.; Sarafianos, S.G.; Anderson, K.S. Probing the molecular mechanism of action of the hiv-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (efda) using pre-steady-state kinetics. Antivir. Res. 2014, 106, 1-4.
144. Yang, G.; Dutschman, G.E.; Wang, C.J.; Tanaka, H.; Baba, M.; Anderson, K.S.; Cheng, Y.C. Highly selective action of triphosphate metabolite of 4'-ethynyl d4t: A novel anti-hiv compound against hiv-1 rt. Antivir. Res. 2007, 73, 185-191.
145. Dutschman, G.E.; Grill, S.P.; Gullen, E.A.; Haraguchi, K.; Takeda, S.; Tanaka, H.; Baba, M.; Cheng, Y.C. Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob. Agents Chemother. 2004, 48, 1640-1646.
146. Li, Z.; Terry, B.; Olds, W.; Protack, T.; Deminie, C.; Minassian, B.; Nowicka-Sans, B.; Sun, Y.; Dicker, I.; Hwang, C., et al. In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (nrti) bms-986001 against known nrti resistance mutations. Antimicrob. Agents Chemother. 2013, 57, 5500-5508.
147. Yang, G.; Paintsil, E.; Dutschman, G.E.; Grill, S.P.; Wang, C.J.; Wang, J.; Tanaka, H.; Hamasaki, T.; Baba, M.; Cheng, Y.C. Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations p119s and t165a on 4'-ethynylthymidine analog resistance profile. Antimicrob. Agents Chemother. 2009, 53, 4640-4646.
148. Das, K.; Arnold, E. Hiv-1 reverse transcriptase and antiviral drug resistance. Part 1. Curr. Opin. Virol. 2013, 3, 111-118.
149. Spence, R.A.; Kati, W.M.; Anderson, K.S.; Johnson, K.A. Mechanism of inhibition of hiv-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267, 988-993.
150. Rittinger, K.; Divita, G.; Goody, R.S. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 1995, 92, 8046-8049.
151. Xia, Q.; Radzio, J.; Anderson, K.S.; Sluis-Cremer, N. Probing nonnucleoside inhibitor-induced active-site distortion in hiv-1 reverse transcriptase by transient kinetic analyses. Protein Sci. 2007, 16, 1728-1737.
152. Ren, J.; Milton, J.; Weaver, K.L.; Short, S.A.; Stuart, D.I.; Stammers, D.K. Structural basis for the resilience of efavirenz (dmp-266) to drug resistance mutations in hiv-1 reverse transcriptase. Struct. Fold Des. 2000, 8, 1089-1094.
153. Martins, S.; Ramos, M.J.; Fernandes, P.A. The current status of the nnrti family of antiretrovirals used in the haart regime against hiv infection. Curr. Med. Chem. 2008, 15, 1083-1095.
154. Hu, Z.; Kuritzkes, D.R. Altered viral fitness and drug susceptibility in human inmmunodeficiency virus type 1 (hiv-1) carrying mutations that confer resistance to non-nucleoside reverse transcriptase and integrase strand-transfer inhibitors. J. Virol. 2014, 88, 9268-9276.
155. Merluzzi, V.J.; Hargrave, K.D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J.C.; Shih, C.K.; Eckner, K.; Hattox, S.; Adams, J., et al. Inhibition of hiv-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990, 250, 1411-1413.
156. Dueweke, T.J.; Poppe, S.M.; Romero, D.L.; Swaney, S.M.; So, A.G.; Downey, K.M.; Althaus, I.W.; Reusser, F.; Busso, M.; Resnick, L., et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 1993, 37, 1127-1131.
157. Young, S.D.; Britcher, S.F.; Tran, L.O.; Payne, L.S.; Lumma, W.C.; Lyle, T.A.; Huff, J.R.; Anderson, P.S.; Olsen, D.B.; Carroll, S.S., et al. L-743, 726 (dmp-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1995, 39, 2602-2605.
158. Andries, K.; Azijn, H.; Thielemans, T.; Ludovici, D.; Kukla, M.; Heeres, J.; Janssen, P.; de Corte, B.; Vingerhoets, J.; Pauwels, R., et al. Tmc125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2004, 48, 4680-4686.
159. Janssen, P.A.; Lewi, P.J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E., et al. In search of a novel anti-hiv drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1e)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (r278474, rilpivirine). J. Med. Chem. 2005, 48, 1901-1909.
160. Soriano, V.; de Mendoza, C. Genetic mechanisms of resistance to nrti and nnrti. HIV Clin. Trials 2002, 3, 237-248.
161. Kohlstaedt, L.A.; Wang, J.; Friedman, J.M.; Rice, P.A.; Steitz, T.A. Crystal structure at 3.5 a resolution of hiv-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
162. Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of inhibition of hiv-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 303-308.
163. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents; Office of Aids Research Advisory Council: Bethesda, USA, 2011; pp. 1-174.
164. Deparment of Health and Human Services-A working group of the office of AIDS research advisory council. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents; 2014; pp. 1-284. Available online: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed on 15 October 2014)
165. Tambuyzer, L.; Azijn, H.; Rimsky, L.T.; Vingerhoets, J.; Lecocq, P.; Kraus, G.; Picchio, G.; deBethune, M.P. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir. Therapy 2009, 14, 103-109.
166. Hsiou, Y.; Ding, J.; Das, K.; Clark, A.D., Jr.; Boyer, P.L.; Lewi, P.; Janssen, P.A.; Kleim, J.P.; Rosner, M.; Hughes, S.H., et al. The lys103asn mutation of hiv-1 rt: A novel mechanism of drug resistance. J. Mol. Biol. 2001, 309, 437-445.
167. Lindberg, J.; Sigurdsson, S.; Lowgren, S.; Andersson, H.O.; Sahlberg, C.; Noreen, R.; Fridborg, K.; Zhang, H.; Unge, T. Structural basis for the inhibitory efficacy of efavirenz (dmp-266), msc194 and pnu142721 towards the hiv-1 rt k103n mutant. Eur. J. Biochem./FEBS 2002, 269, 1670-1677.
168. Harrigan, P.R.; Mo, T.; Wynhoven, B.; Hirsch, J.; Brumme, Z.; McKenna, P.; Pattery, T.; Vingerhoets, J.; Bacheler, L.T. Rare mutations at codon 103 of hiv-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2005, 19, 549-554.
169. Parkin, N.T.; Gupta, S.; Chappey, C.; Petropoulos, C.J. The k101p and k103r/v179d mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 2006, 50, 351-354.
170. Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D., et al. High resolution structures of hiv-1 rt from four rt-inhibitor complexes. Nat. Struct. Biol. 1995, 2, 293-302.
171. DeClercq, E. Non-nucleoside reverse transcriptase inhibitors (nnrtis): Past, present, and future. Chem. Biodivers. 2004, 1, 44-64.
172. Petropoulos, C.J.; Parkin, N.T.; Limoli, K.L.; Lie, Y.S.; Wrin, T.; Huang, W.; Tian, H.; Smith, D.; Winslow, G.A.; Capon, D.J., et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2000, 44, 920-928.
173. Walmsley, S.L.; Kelly, D.V.; Tseng, A.L.; Humar, A.; Harrigan, P.R. Non-nucleoside reverse transcriptase inhibitor failure impairs hiv-rna responses to efavirenz-containing salvage antiretroviral therapy. AIDS 2001, 15, 1581-1584.
174. Delaugerre, C.; Rohban, R.; Simon, A.; Mouroux, M.; Tricot, C.; Agher, R.; Huraux, J.M.; Katlama, C.; Calvez, V. Resistance profile and cross-resistance of hiv-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J. Med. Virol. 2001, 65, 445-448.
175. Bacheler, L.; Jeffrey, S.; Hanna, G.; D’Aquila, R.; Wallace, L.; Logue, K.; Cordova, B.; Hertogs, K.; Larder, B.; Buckery, R., et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 2001, 75, 4999-5008.
176. Huang, W.; Gamarnik, A.; Limoli, K.; Petropoulos, C.J.; Whitcomb, J.M. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J. Virol. 2003, 77, 1512-1523.
177. Kleim, J.P.; Bender, R.; Kirsch, R.; Meichsner, C.; Paessens, A.; Riess, G. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology 1994, 200, 696-701.
178. Ludovici, D.W.; de Corte, B.L.; Kukla, M.J.; Ye, H.; Ho, C.Y.; Lichtenstein, M.A.; Kavash, R.W.; Andries, K.; de Bethune, M.P.; Azijn, H., et al. Evolution of anti-hiv drug candidates. Part 3: Diarylpyrimidine (dapy) analogues. Bioorganic Med. Chem. Lett. 2001, 11, 2235-2239.
179. Vingerhoets, J.; Azijn, H.; Fransen, E.; de Baere, I.; Smeulders, L.; Jochmans, D.; Andries, K.; Pauwels, R.; de Bethune, M.P. Tmc125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J. Virol. 2005, 79, 12773-12782.
180. Das, K.; Clark, A.D., Jr.; Lewi, P.J.; Heeres, J.; de Jonge, M.R.; Koymans, L.M.; Vinkers, H.M.; Daeyaert, F.; Ludovici, D.W.; Kukla, M.J., et al. Roles of conformational and positional adaptability in structure-based design of tmc125-r165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant hiv-1 variants. J. Med. Chem. 2004, 47, 2550-2560.
181. Das, K.; Bauman, J.D.; Clark, A.D., Jr.; Frenkel, Y.V.; Lewi, P.J.; Shatkin, A.J.; Hughes, S.H.; Arnold, E. High-resolution structures of hiv-1 reverse transcriptase/tmc278 complexes: Strategic flexibility explains potency against resistance mutations. Proc. Natl. Acad. Sci. USA 2008, 105, 1466-1471.
182. Lansdon, E.B.; Brendza, K.M.; Hung, M.; Wang, R.; Mukund, S.; Jin, D.; Birkus, G.; Kutty, N.; Liu, X. Crystal structures of hiv-1 reverse transcriptase with etravirine (tmc125) and rilpivirine (tmc278): Implications for drug design. J. Med. Chem. 2010, 53, 4295-4299.
183. Xu, H.T.; Quan, Y.; Schader, S.M.; Oliveira, M.; Bar-Magen, T.; Wainberg, M.A. The m230l nonnucleoside reverse transcriptase inhibitor resistance mutation in hiv-1 reverse transcriptase impairs enzymatic function and viral replicative capacity. Antimicrob. Agents Chemother. 2010, 54, 2401-2408.
184. Madruga, J.V.; Cahn, P.; Grinsztejn, B.; Haubrich, R.; Lalezari, J.; Mills, A.; Pialoux, G.; Wilkin, T.; Peeters, M.; Vingerhoets, J., et al. Efficacy and safety of tmc125 (etravirine) in treatment-experienced hiv-1-infected patients in duet-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370, 29-38.
185. Lazzarin, A.; Campbell, T.; Clotet, B.; Johnson, M.; Katlama, C.; Moll, A.; Towner, W.; Trottier, B.; Peeters, M.; Vingerhoets, J., et al. Efficacy and safety of tmc125 (etravirine) in treatment-experienced hiv-1-infected patients in duet-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370, 39-48.
186. Vingerhoets, J.; Tambuyzer, L.; Azijn, H.; Hoogstoel, A.; Nijs, S.; Peeters, M.; de Bethune, M.P.; de Smedt, G.; Woodfall, B.; Picchio, G. Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase iii clinical studies. AIDS 2010, 24, 503-514.
187. Towner, W.J.; Cassetti, I.; Domingo, P.; Nijs, S.; Kakuda, T.N.; Vingerhoets, J.; Woodfall, B. Etravirine: Clinical review of a treatment option for hiv type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antivir. Therapy 2010, 15, 803-816.
188. Marcelin, A.G.; Flandre, P.; Descamps, D.; Morand-Joubert, L.; Charpentier, C.; Izopet, J.; Trabaud, M.A.; Saoudin, H.; Delaugerre, C.; Tamalet, C., et al. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced hiv-1-infected patients. Antimicrob. Agents Chemother. 2010, 54, 72-77.
189. Xu, H.T.; Colby-Germinario, S.P.; Asahchop, E.L.; Oliveira, M.; McCallum, M.; Schader, S.M.; Han, Y.; Quan, Y.; Sarafianos, S.G.; Wainberg, M.A. Effect of mutations at position e138 in hiv-1 reverse transcriptase and their interactions with the m184i mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine. Antimicrob. Agents Chemother. 2013, 57, 3100-3109.
190. Xu, H.T.; Oliveira, M.; Asahchop, E.L.; McCallum, M.; Quashie, P.K.; Han, Y.; Quan, Y.; Wainberg, M.A. Molecular mechanism of antagonism between the y181c and e138k mutations in hiv-1 reverse transcriptase. J. Virol. 2012, 86, 12983-12990.
191. Poveda, E.; de Mendoza, C.; Pattery, T.; Gonzalez Mdel, M.; Villacian, J.; Soriano, V. Phenotypic impact of resistance mutations on etravirine susceptibility in hiv patients with prior failure to nonnucleoside analogues. AIDS 2008, 22, 2395-2398.
192. Gupta, S.; Vingerhoets, J.; Fransen, S.; Tambuyzer, L.; Azijn, H.; Frantzell, A.; Paredes, R.; Coakley, E.; Nijs, S.; Clotet, B., et al. Connection domain mutations in hiv-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens. Antimicrob. Agents Chemother. 2011, 55, 2872-2879.
193. Xu, H.T.; Colby-Germinario, S.P.; Oliveira, M.; Han, Y.; Quan, Y.; Zanichelli, V.; Wainberg, M.A. The connection domain mutation n348i in hiv-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the e138k resistance mutation by diminishing viral replication capacity. J. Virol. 2014, 88, 1536-1547.
194. Sharma, M.; Saravolatz, L.D. Rilpivirine: A new non-nucleoside reverse transcriptase inhibitor. J. Antimicrob. Chemother. 2013, 68, 250-256.
195. Johnson, B.C.; Pauly, G.T.; Rai, G.; Patel, D.; Bauman, J.D.; Baker, H.L.; Das, K.; Schneider, J.P.; Maloney, D.J.; Arnold, E., et al. A comparison of the ability of rilpivirine (tmc278) and selected analogues to inhibit clinically relevant hiv-1 reverse transcriptase mutants. Retrovirology 2012, 9, 99.
196. Asahchop, E.L.; Wainberg, M.A.; Oliveira, M.; Xu, H.; Brenner, B.G.; Moisi, D.; Ibanescu, I.R.; Tremblay, C. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. AIDS 2013, 27, 879-887.
197. Xu, H.T.; Colby-Germinario, S.P.; Huang, W.; Oliveira, M.; Han, Y.; Quan, Y.; Petropoulos, C.J.; Wainberg, M.A. Role of the k101e substitution in hiv-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 2013, 57, 5649-5657.
198. Singh, K.; Marchand, B.; Rai, D.K.; Sharma, B.; Michailidis, E.; Ryan, E.M.; Matzek, K.B.; Leslie, M.D.; Hagedorn, A.N.; Li, Z., et al. Biochemical mechanism of hiv-1 resistance to rilpivirine. J. Biol. Chem. 2012, 287, 38110-38123.
199. Rimsky, L.; Van Eygen, V.; Hoogstoel, A.; Stevens, M.; Boven, K.; Picchio, G.; Vingerhoets, J. 96-week resistance analyses of rilpivirine in treatment-naive, hiv-1-infected adults from the echo and thrive phase iii trials. Antivir. Therapy 2013, 18, 967-977.
200. Kohl, N.E.; Emini, E.A.; Schleif, W.A.; Davis, L.J.; Heimbach, J.C.; Dixon, R.A.; Scolnick, E.M.; Sigal, I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 1988, 85, 4686-4690.
201. Roberts, N.A.; Martin, J.A.; Kinchington, D.; Broadhurst, A.V.; Craig, J.C.; Duncan, I.B.; Galpin, S.A.; Handa, B.K.; Kay, J.; Krohn, A., et al. Rational design of peptide-based hiv proteinase inhibitors. Science 1990, 248, 358-361.
202. Huff, J.R.; Kahn, J. Discovery and clinical development of hiv-1 protease inhibitors. Adv. Protein Chem. 2001, 56, 213-251.
203. Louis, J.M.; Ishima, R.; Torchia, D.A.; Weber, I.T. Hiv-1 protease: Structure, dynamics, and inhibition. Adv. Pharmacol. 2007, 55, 261-298.
204. Hull, M.W.; Montaner, J.S. Ritonavir-boosted protease inhibitors in hiv therapy. Ann. Med. 2011, 43, 375-388.
205. Kempf, D.J.; Marsh, K.C.; Kumar, G.; Rodrigues, A.D.; Denissen, J.F.; McDonald, E.; Kukulka, M.J.; Hsu, A.; Granneman, G.R.; Baroldi, P.A., et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 1997, 41, 654-660.
206. Stanford HIV Drug Resistance Database. Major HIV-1 drug resistance mutations. Available online: http://hivdb.Stanford.edu (accessed on 16 June 2014).
207. Swain, A.L.; Miller, M.M.; Green, J.; Rich, D.H.; Schneider, J.; Kent, S.B.; Wlodawer, A. X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. Proc. Natl. Acad. Sci. USA 1990, 87, 8805-8809.
208. Gulnik, S.V.; Suvorov, L.I.; Liu, B.; Yu, B.; Anderson, B.; Mitsuya, H.; Erickson, J.W. Kinetic characterization and cross-resistance patterns of hiv-1 protease mutants selected under drug pressure. Biochemistry 1995, 34, 9282-9287.
209. Johnson, V.A.; Calvez, V.; Gunthard, H.F.; Paredes, R.; Pillay, D.; Shafer, R.; Wensing, A.M.; Richman, D.D. 2011 update of the drug resistance mutations in hiv-1. Top. Antivir. Med. 2011, 19, 156-164.
210. Markowitz, M.; Conant, M.; Hurley, A.; Schluger, R.; Duran, M.; Peterkin, J.; Chapman, S.; Patick, A.; Hendricks, A.; Yuen, G.J., et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (hiv)-1 protease, to treat hiv infection. J. Infect. Dis. 1998, 177, 1533-1540.
211. Rhee, S.Y.; Taylor, J.; Fessel, W.J.; Kaufman, D.; Towner, W.; Troia, P.; Ruane, P.; Hellinger, J.; Shirvani, V.; Zolopa, A., et al. Hiv-1 protease mutations and protease inhibitor cross-resistance. Antimicrob. Agents Chemother. 2010, 54, 4253-4261.
212. Mahalingam, B.; Louis, J.M.; Reed, C.C.; Adomat, J.M.; Krouse, J.; Wang, Y.F.; Harrison, R.W.; Weber, I.T. Structural and kinetic analysis of drug resistant mutants of hiv-1 protease. Eur. J. Biochem./FEBS 1999, 263, 238-245.
213. Prabu-Jeyabalan, M.; Nalivaika, E.; Schiffer, C.A. Substrate shape determines specificity of recognition for hiv-1 protease: Analysis of crystal structures of six substrate complexes. Structure 2002, 10, 369-381.
214. King, N.M.; Prabu-Jeyabalan, M.; Nalivaika, E.A.; Schiffer, C.A. Combating susceptibility to drug resistance: Lessons from hiv-1 protease. Chem. Biol. 2004, 11, 1333-1338.
215. King, N.M.; Melnick, L.; Prabu-Jeyabalan, M.; Nalivaika, E.A.; Yang, S.S.; Gao, Y.; Nie, X.; Zepp, C.; Heefner, D.L.; Schiffer, C.A. Lack of synergy for inhibitors targeting a multi-drug-resistant hiv-1 protease. Protein Sci. 2002, 11, 418-429.
216. Munshi, S.; Chen, Z.; Yan, Y.; Li, Y.; Olsen, D.B.; Schock, H.B.; Galvin, B.B.; Dorsey, B.; Kuo, L.C. An alternate binding site for the p1-p3 group of a class of potent hiv-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease. Acta Crystallogr. Sect. D Biol. Crystallogr. 2000, 56, 381-388.
217. Johnson, V.A.; Calvez, V.; Gunthard, H.F.; Paredes, R.; Pillay, D.; Shafer, R.W.; Wensing, A.M.; Richman, D.D. Update of the drug resistance mutations in hiv-1: March 2013. Top. Antivir. Med. 2013, 21, 6-14.
218. Kaldor, S.W.; Kalish, V.J.; Davies, J.F., II; Shetty, B.V.; Fritz, J.E.; Appelt, K.; Burgess, J.A.; Campanale, K.M.; Chirgadze, N.Y.; Clawson, D.K., et al. Viracept (nelfinavir mesylate, ag1343): A potent, orally bioavailable inhibitor of hiv-1 protease. J. Med. Chem. 1997, 40, 3979-3985.
219. Sugiura, W.; Matsuda, Z.; Yokomaku, Y.; Hertogs, K.; Larder, B.; Oishi, T.; Okano, A.; Shiino, T.; Tatsumi, M.; Matsuda, M., et al. Interference between d30n and l90m in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2002, 46, 708-715.
220. Menendez-Arias, L.; Martinez, M.A.; Quinones-Mateu, M.E.; Martinez-Picado, J. Fitness variations and their impact on the evolution of antiretroviral drug resistance. Curr. Drug Targets 2003, 3, 355-371.
221. Chang, M.W.; Torbett, B.E. Accessory mutations maintain stability in drug-resistant hiv-1 protease. J. Mol. Biol. 2011, 410, 756-760.
222. Zhang, Y.M.; Imamichi, H.; Imamichi, T.; Lane, H.C.; Falloon, J.; Vasudevachari, M.B.; Salzman, N.P. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. J. Virol. 1997, 71, 6662-6670.
223. Doyon, L.; Croteau, G.; Thibeault, D.; Poulin, F.; Pilote, L.; Lamarre, D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 1996, 70, 3763-3769.
224. Robinson, L.H.; Myers, R.E.; Snowden, B.W.; Tisdale, M.; Blair, E.D. Hiv type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays. AIDS Res. Hum. Retrovir. 2000, 16, 1149-1156.
225. Pettit, S.C.; Henderson, G.J.; Schiffer, C.A.; Swanstrom, R. Replacement of the p1 amino acid of human immunodeficiency virus type 1 gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J. Virol. 2002, 76, 10226-10233.
226. Feher, A.; Weber, I.T.; Bagossi, P.; Boross, P.; Mahalingam, B.; Louis, J.M.; Copeland, T.D.; Torshin, I.Y.; Harrison, R.W.; Tozser, J. Effect of sequence polymorphism and drug resistance on two hiv-1 gag processing sites. Eur. J. Biochem./FEBS 2002, 269, 4114-4120.
227. Doyon, L.; Payant, C.; Brakier-Gingras, L.; Lamarre, D. Novel gag-pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J. Virol. 1998, 72, 6146-6150.
228. Gatanaga, H.; Suzuki, Y.; Tsang, H.; Yoshimura, K.; Kavlick, M.F.; Nagashima, K.; Gorelick, R.J.; Mardy, S.; Tang, C.; Summers, M.F., et al. Amino acid substitutions in gag protein at non-cleavage sites are indispensable for the development of a high multitude of hiv-1 resistance against protease inhibitors. J. Biol. Chem. 2002, 277, 5952-5961.
229. Dam, E.; Quercia, R.; Glass, B.; Descamps, D.; Launay, O.; Duval, X.; Krausslich, H.G.; Hance, A.J.; Clavel, F.; Group, A.S. Gag mutations strongly contribute to hiv-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog. 2009, 5, e1000345.
230. Myint, L.; Matsuda, M.; Matsuda, Z.; Yokomaku, Y.; Chiba, T.; Okano, A.; Yamada, K.; Sugiura, W. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2004, 48, 444-452.
231. Grant, P.; Wong, E.C.; Rode, R.; Shafer, R.; de Luca, A.; Nadler, J.; Hawkins, T.; Cohen, C.; Harrington, R.; Kempf, D., et al. Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: Comparison of genotypic interpretation scores. Antimicrob. Agents Chemother. 2008, 52, 4050-4056.
232. Becker, S.; Thornton, L. Fosamprenavir: Advancing hiv protease inhibitor treatment options. Expert Opin. Pharmacother. 2004, 5, 1995-2005.
233. Marcelin, A.G.; Masquelier, B.; Descamps, D.; Izopet, J.; Charpentier, C.; Alloui, C.; Bouvier-Alias, M.; Signori-Schmuck, A.; Montes, B.; Chaix, M.L., et al. Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 2008, 52, 3237-3243.
234. De Meyer, S.; Hill, A.; Picchio, G.; DeMasi, R.; de Paepe, E.; de Bethune, M.P. Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the titan trial. J. Acquir. Immune Defic. Syndr. 2008, 49, 563-564.
235. Ali, A.; Bandaranayake, R.M.; Cai, Y.; King, N.M.; Kolli, M.; Mittal, S.; Murzycki, J.F.; Nalam, M.N.; Nalivaika, E.A.; Ozen, A., et al. Molecular basis for drug resistance in hiv-1 protease. Viruses 2010, 2, 2509-2535.
236. Ghosh, A.K.; Parham, G.L.; Martyr, C.D.; Nyalapatla, P.R.; Osswald, H.L.; Agniswamy, J.; Wang, Y.F.; Amano, M.; Weber, I.T.; Mitsuya, H. Highly potent hiv-1 protease inhibitors with novel tricyclic p2 ligands: Design, synthesis, and protein-ligand x-ray studies. J. Med. Chem. 2013, 56, 6792-6802.
237. Chow, S.A.; Vincent, K.A.; Ellison, V.; Brown, P.O. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 1992, 255, 723-726.
238. Engelman, A.; Bushman, F.D.; Craigie, R. Identification of discrete functional domains of hiv-1 integrase and their organization within an active multimeric complex. EMBO J. 1993, 12, 3269-3275.
239. Hazuda, D.J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J.A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C., et al. Inhibitors of strand transfer that prevent integration and inhibit hiv-1 replication in cells. Science 2000, 287, 646-650.
240. Delelis, O.; Carayon, K.; Saib, A.; Deprez, E.; Mouscadet, J.F. Integrase and integration: Biochemical activities of hiv-1 integrase. Retrovirology 2008, 5, 114.
241. Craigie, R. The molecular biology of hiv integrase. Future Virol. 2012, 7, 679-686.
242. Metifiot, M.; Marchand, C.; Pommier, Y. Hiv integrase inhibitors: 20-year landmark and challenges. Adv. Pharmacol. 2013, 67, 75-105.
243. Hazuda, D.J.; Felock, P.J.; Hastings, J.C.; Pramanik, B.; Wolfe, A.L. Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. J. Virol. 1997, 71, 7005-7011.
244. Hicks, C.; Gulick, R.M. Raltegravir: The first hiv type 1 integrase inhibitor. Clin. Infect. Dis. 2009, 48, 931-939.
245. Cooper, D.A.; Steigbigel, R.T.; Gatell, J.M.; Rockstroh, J.K.; Katlama, C.; Yeni, P.; Lazzarin, A.; Clotet, B.; Kumar, P.N.; Eron, J.E., et al. Subgroup and resistance analyses of raltegravir for resistant hiv-1 infection. N. Engl. J. Med. 2008, 359, 355-365.
246. Canducci, F.; Sampaolo, M.; Marinozzi, M.C.; Boeri, E.; Spagnuolo, V.; Galli, A.; Castagna, A.; Lazzarin, A.; Clementi, M.; Gianotti, N. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009, 23, 455-460.
247. Hurt, C.B.; Sebastian, J.; Hicks, C.B.; Eron, J.J. Resistance to hiv integrase strand transfer inhibitors among clinical specimens in the united states, 2009-2012. Clin. Infect. Dis. 2014, 58, 423-431.
248. Malet, I.; Delelis, O.; Valantin, M.A.; Montes, B.; Soulie, C.; Wirden, M.; Tchertanov, L.; Peytavin, G.; Reynes, J.; Mouscadet, J.F., et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 2008, 52, 1351-1358.
249. Nakahara, K.; Wakasa-Morimoto, C.; Kobayashi, M.; Miki, S.; Noshi, T.; Seki, T.; Kanamori-Koyama, M.; Kawauchi, S.; Suyama, A.; Fujishita, T., et al. Secondary mutations in viruses resistant to hiv-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antivir. Res. 2009, 81, 141-146.
250. Delelis, O.; Malet, I.; Na, L.; Tchertanov, L.; Calvez, V.; Marcelin, A.G.; Subra, F.; Deprez, E.; Mouscadet, J.F. The g140s mutation in hiv integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance q148h mutation. Nucleic Acids Res. 2009, 37, 1193-1201.
251. Marchand, C. The elvitegravir quad pill: The first once-daily dual-target anti-hiv tablet. Expert Opin. Investig. Drugs 2012, 21, 901-904.
252. Blanco, J.L.; Varghese, V.; Rhee, S.Y.; Gatell, J.M.; Shafer, R.W. Hiv-1 integrase inhibitor resistance and its clinical implications. J. Infect. Dis. 2011, 203, 1204-1214.
253. Goethals, O.; Clayton, R.; van Ginderen, M.; Vereycken, I.; Wagemans, E.; Geluykens, P.; Dockx, K.; Strijbos, R.; Smits, V.; Vos, A., et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J. Virol. 2008, 82, 10366-10374.
254. Shimura, K.; Kodama, E.; Sakagami, Y.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Watanabe, Y.; Ohata, Y.; Doi, S.; Sato, M., et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (jtk-303/gs-9137). J. Virol. 2008, 82, 764-774.
255. Kobayashi, M.; Yoshinaga, T.; Seki, T.; Wakasa-Morimoto, C.; Brown, K.W.; Ferris, R.; Foster, S.A.; Hazen, R.J.; Miki, S.; Suyama-Kagitani, A., et al. In vitro antiretroviral properties of s/gsk1349572, a next-generation hiv integrase inhibitor. Antimicrob. Agents Chemother. 2011, 55, 813-821.
256. Hightower, K.E.; Wang, R.; Deanda, F.; Johns, B.A.; Weaver, K.; Shen, Y.; Tomberlin, G.H.; Carter, H.L., III; Broderick, T.; Sigethy, S., et al. Dolutegravir (s/gsk1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant hiv-1 integrase-DNA complexes. Antimicrob. Agents Chemother. 2011, 55, 4552-4559.
257. Eron, J.J.; Clotet, B.; Durant, J.; Katlama, C.; Kumar, P.; Lazzarin, A.; Poizot-Martin, I.; Richmond, G.; Soriano, V.; Ait-Khaled, M., et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant hiv type 1 infection: 24-week results of the viking study. J. Infect. Dis. 2013, 207, 740-748.
258. Quashie, P.K.; Mesplede, T.; Han, Y.S.; Oliveira, M.; Singhroy, D.N.; Fujiwara, T.; Underwood, M.R.; Wainberg, M.A. Characterization of the r263k mutation in hiv-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J. Virol. 2012, 86, 2696-2705.
259. Cahn, P.; Pozniak, A.L.; Mingrone, H.; Shuldyakov, A.; Brites, C.; Andrade-Villanueva, J.F.; Richmond, G.; Buendia, C.B.; Fourie, J.; Ramgopal, M., et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with hiv: Week 48 results from the randomised, double-blind, non-inferiority sailing study. Lancet 2013, 382, 700-708.
260. Mesplede, T.; Quashie, P.K.; Osman, N.; Han, Y.; Singhroy, D.N.; Lie, Y.; Petropoulos, C.J.; Huang, W.; Wainberg, M.A. Viral fitness cost prevents hiv-1 from evading dolutegravir drug pressure. Retrovirology 2013, 10, 22.
261. Quashie, P.K.; Mesplede, T.; Han, Y.S.; Veres, T.; Osman, N.; Hassounah, S.; Sloan, R.D.; Xu, H.T.; Wainberg, M.A. Biochemical analysis of the role of g118r-linked dolutegravir drug resistance substitutions in hiv-1 integrase. Antimicrob. Agents Chemother. 2014, 58, 3580.
262. Oliveira, M.; Mesplede, T.; Quashie, P.K.; Moisi, D.; Wainberg, M.A. Resistance mutations against dolutegravir in hiv integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 2014, 28, 813-819.
263. Haqqani, A.A.; Tilton, J.C. Entry inhibitors and their use in the treatment of hiv-1 infection. Antivir. Res. 2013, 98, 158-170.
264. De Feo, C.J.; Weiss, C.D. Escape from human immunodeficiency virus type 1 (hiv-1) entry inhibitors. Viruses 2012, 4, 3859-3911.
265. Cheng-Mayer, C.; Quiroga, M.; Tung, J.W.; Dina, D.; Levy, J.A. Viral determinants of human immunodeficiency virus type 1 t-cell or macrophage tropism, cytopathogenicity, and cd4 antigen modulation. J. Virol. 1990, 64, 4390-4398.
266. Berger, E.A. Hiv entry and tropism: The chemokine receptor connection. AIDS 1997, 11 Suppl A, S3-S16.
267. Picchio, G.R.; Gulizia, R.J.; Wehrly, K.; Chesebro, B.; Mosier, D.E. The cell tropism of human immunodeficiency virus type 1 determines the kinetics of plasma viremia in scid mice reconstituted with human peripheral blood leukocytes. J. Virol. 1998, 72, 2002-2009.
268. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; di Marzio, P.; Marmon, S.; Sutton, R.E.; Hill, C.M., et al. Identification of a major co-receptor for primary isolates of hiv-1. Nature 1996, 381, 661-666.
269. Feng, Y.; Broder, C.C.; Kennedy, P.E.; Berger, E.A. Hiv-1 entry cofactor: Functional cdna cloning of a seven-transmembrane, g protein-coupled receptor. Science 1996, 272, 872-877.
270. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C., et al. Maraviroc (uk-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor ccr5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005, 49, 4721-4732.
271. Dragic, T.; Trkola, A.; Thompson, D.A.; Cormier, E.G.; Kajumo, F.A.; Maxwell, E.; Lin, S.W.; Ying, W.; Smith, S.O.; Sakmar, T.P., et al. A binding pocket for a small molecule inhibitor of hiv-1 entry within the transmembrane helices of ccr5. Proc. Natl. Acad. Sci. USA 2000, 97, 5639-5644.
272. Roche, M.; Jakobsen, M.R.; Sterjovski, J.; Ellett, A.; Posta, F.; Lee, B.; Jubb, B.; Westby, M.; Lewin, S.R.; Ramsland, P.A., et al. Hiv-1 escape from the ccr5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-ccr5 engagement that attenuates macrophage tropism. J. Virol. 2011, 85, 4330-4342.
273. Fatkenheuer, G.; Nelson, M.; Lazzarin, A.; Konourina, I.; Hoepelman, A.I.; Lampiris, H.; Hirschel, B.; Tebas, P.; Raffi, F.; Trottier, B., et al. Subgroup analyses of maraviroc in previously treated r5 hiv-1 infection. N. Engl. J. Med. 2008, 359, 1442-1455.
274. Gulick, R.M.; Lalezari, J.; Goodrich, J.; Clumeck, N.; DeJesus, E.; Horban, A.; Nadler, J.; Clotet, B.; Karlsson, A.; Wohlfeiler, M., et al. Maraviroc for previously treated patients with r5 hiv-1 infection. N. Engl. J. Med. 2008, 359, 1429-1441.
275. Moore, J.P.; Kuritzkes, D.R. A piece de resistance: How hiv-1 escapes small molecule ccr5 inhibitors. Curr. Opin. HIV AIDS 2009, 4, 118-124.
276. Pastore, C.; Ramos, A.; Mosier, D.E. Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J. Virol. 2004, 78, 7565-7574.
277. Pastore, C.; Nedellec, R.; Ramos, A.; Pontow, S.; Ratner, L.; Mosier, D.E. Human immunodeficiency virus type 1 coreceptor switching: V1/v2 gain-of-fitness mutations compensate for v3 loss-of-fitness mutations. J. Virol. 2006, 80, 750-758.
278. Westby, M. Resistance to ccr5 antagonists. Curr. Opin. HIV AIDS 2007, 2, 137-144.
279. Westby, M.; Smith-Burchnell, C.; Mori, J.; Lewis, M.; Mosley, M.; Stockdale, M.; Dorr, P.; Ciaramella, G.; Perros, M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the ccr5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 2007, 81, 2359-2371.
280. Anastassopoulou, C.G.; Ketas, T.J.; Klasse, P.J.; Moore, J.P. Resistance to ccr5 inhibitors caused by sequence changes in the fusion peptide of hiv-1 gp41. Proc. Natl. Acad. Sci. USA 2009, 106, 5318-5323.
281. Yuan, Y.; Maeda, Y.; Terasawa, H.; Monde, K.; Harada, S.; Yusa, K. A combination of polymorphic mutations in v3 loop of hiv-1 gp120 can confer noncompetitive resistance to maraviroc. Virology 2011, 413, 293-299.
282. Berro, R.; Klasse, P.J.; Jakobsen, M.R.; Gorry, P.R.; Moore, J.P.; Sanders, R.W. V3 determinants of hiv-1 escape from the ccr5 inhibitors maraviroc and vicriviroc. Virology 2012, 427, 158-165.
283. Kilby, J.M.; Hopkins, S.; Venetta, T.M.; DiMassimo, B.; Cloud, G.A.; Lee, J.Y.; Alldredge, L.; Hunter, E.; Lambert, D.; Bolognesi, D., et al. Potent suppression of hiv-1 replication in humans by t-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 1998, 4, 1302-1307.
284. Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D. Enfuvirtide: The first therapy to inhibit the entry of hiv-1 into host cd4 lymphocytes. Nat. Rev. 2004, 3, 215-225.
285. Rimsky, L.T.; Shugars, D.C.; Matthews, T.J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 1998, 72, 986-993.
286. Wei, X.; Decker, J.M.; Liu, H.; Zhang, Z.; Arani, R.B.; Kilby, J.M.; Saag, M.S.; Wu, X.; Shaw, G.M.; Kappes, J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (t-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46, 1896-1905.
287. Poveda, E.; Rodes, B.; Toro, C.; Martin-Carbonero, L.; Gonzalez-Lahoz, J.; Soriano, V. Evolution of the gp41 env region in hiv-infected patients receiving t-20, a fusion inhibitor. AIDS 2002, 16, 1959-1961.
288. Sista, P.R.; Melby, T.; Davison, D.; Jin, L.; Mosier, S.; Mink, M.; Nelson, E.L.; DeMasi, R.; Cammack, N.; Salgo, M.P., et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment hiv-1 isolates. AIDS 2004, 18, 1787-1794.
289. Poveda, E.; Rodes, B.; Lebel-Binay, S.; Faudon, J.L.; Jimenez, V.; Soriano, V. Dynamics of enfuvirtide resistance in hiv-infected patients during and after long-term enfuvirtide salvage therapy. J. Clin. Virol. 2005, 34, 295-301.
290. Cabrera, C.; Marfil, S.; Garcia, E.; Martinez-Picado, J.; Bonjoch, A.; Bofill, M.; Moreno, S.; Ribera, E.; Domingo, P.; Clotet, B., et al. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 2006, 20, 2075-2080.
291. Ray, N.; Harrison, J.E.; Blackburn, L.A.; Martin, J.N.; Deeks, S.G.; Doms, R.W. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J. Virol. 2007, 81, 3240-3250.
292. Xu, L.; Pozniak, A.; Wildfire, A.; Stanfield-Oakley, S.A.; Mosier, S.M.; Ratcliffe, D.; Workman, J.; Joall, A.; Myers, R.; Smit, E., et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob. Agents Chemother. 2005, 49, 1113-1119.
293. Cilliers, T.; Moore, P.; Coetzer, M.; Morris, L. In vitro generation of hiv type 1 subtype c isolates resistant to enfuvirtide. AIDS Res. Hum. Retrovir. 2005, 21, 776-783.
294. Mink, M.; Mosier, S.M.; Janumpalli, S.; Davison, D.; Jin, L.; Melby, T.; Sista, P.; Erickson, J.; Lambert, D.; Stanfield-Oakley, S.A., et al. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 2005, 79, 12447-12454.
295. Menzo, S.; Castagna, A.; Monachetti, A.; Hasson, H.; Danise, A.; Carini, E.; Bagnarelli, P.; Lazzarin, A.; Clementi, M. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob. Agents Chemother. 2004, 48, 3253-3259.
296. Nameki, D.; Kodama, E.; Ikeuchi, M.; Mabuchi, N.; Otaka, A.; Tamamura, H.; Ohno, M.; Fujii, N.; Matsuoka, M. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and rev-responsive element functions. J. Virol. 2005, 79, 764-770.
297. Greenberg, M.L.; Cammack, N. Resistance to enfuvirtide, the first hiv fusion inhibitor. J. Antimicrob. Chemother. 2004, 54, 333-340.
298. Trivedi, V.D.; Cheng, S.F.; Wu, C.W.; Karthikeyan, R.; Chen, C.J.; Chang, D.K. The llsgiv stretch of the n-terminal region of hiv-1 gp41 is critical for binding to a model peptide, t20. Protein Eng. 2003, 16, 311-317.
299. Lu, J.; Sista, P.; Giguel, F.; Greenberg, M.; Kuritzkes, D.R. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (t-20). J. Virol. 2004, 78, 4628-4637.
300. Marconi, V.; Bonhoeffer, S.; Paredes, R.; Lu, J.; Hoh, R.; Martin, J.N.; Deeks, S.G.; Kuritzkes, D.R. Viral dynamics and in vivo fitness of hiv-1 in the presence and absence of enfuvirtide. J. Acquir. Immune Defic. Syndr. 2008, 48, 572-576.
301. Bai, X.; Wilson, K.L.; Seedorff, J.E.; Ahrens, D.; Green, J.; Davison, D.K.; Jin, L.; Stanfield-Oakley, S.A.; Mosier, S.M.; Melby, T.E., et al. Impact of the enfuvirtide resistance mutation n43d and the associated baseline polymorphism e137k on peptide sensitivity and six-helix bundle structure. Biochemistry 2008, 47, 6662-6670.
302. Watabe, T.; Terakawa, Y.; Watanabe, K.; Ohno, H.; Nakano, H.; Nakatsu, T.; Kato, H.; Izumi, K.; Kodama, E.; Matsuoka, M., et al. X-ray crystallographic study of an hiv-1 fusion inhibitor with the gp41 s138a substitution. J. Mol. Biol. 2009, 392, 657-665.
303. Haleyur Giri Setty, M.K.; Hewlett, I.K. Point of care technologies for hiv. AIDS Res. Treat. 2014, 2014, 497046.
304. Siliciano, J.D.; Siliciano, R.F. Recent trends in hiv-1 drug resistance. Curr. Opin. Virol. 2013, 3, 487-494.
305. Lee, H.H.; Dineva, M.A.; Chua, Y.L.; Ritchie, A.V.; Ushiro-Lumb, I.; Wisniewski, C.A. Simple amplification-based assay: A nucleic acid-based point-of-care platform for hiv-1 testing. J. Infect. Dis. 2010, 201 Suppl 1, S65-72.
306. Jordan, M.R.; Bennett, D.E.; Bertagnolio, S.; Gilks, C.F.; Sutherland, D. World health organization surveys to monitor hiv drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir. Therapy 2008, 13 Suppl 2, 15-23.
307. Van den Eede, P.; van Wesenbeeck, L.; Verlinden, Y.; Feyaerts, M.; Smits, V.; Verheyen, A.; Vanhooren, L.; Deloof, A.; Villacian, J.; Pattery, T. Hiv-1 genotyping of the protease-reverse transcriptase and integrase genes to detect mutations that confer antiretroviral resistance. Methods Mol. Biol. 2013, 1030, 37-55.
308. Asahchop, E.L.; Wainberg, M.A.; Sloan, R.D.; Tremblay, C.L. Antiviral drug resistance and the need for development of new hiv-1 reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 2012, 56, 5000-5008.
309. Pirrone, V.; Thakkar, N.; Jacobson, J.M.; Wigdahl, B.; Krebs, F.C. Combinatorial approaches to the prevention and treatment of hiv-1 infection. Antimicrob. Agents Chemother. 2011, 55, 1831-1842.